<?xml version="1.0" encoding="UTF-8"?><rss xmlns:dc="http://purl.org/dc/elements/1.1/" xmlns:content="http://purl.org/rss/1.0/modules/content/" xmlns:atom="http://www.w3.org/2005/Atom" version="2.0"><channel><title><![CDATA[A Cochrane systematic review (April 2026) pooled 17 randomised trials with 20,342 participants.]]></title><description><![CDATA[<p>A Cochrane systematic review (April 2026) pooled 17 randomised trials with 20,342 participants. It found anti-amyloid antibodies give little or no clinically meaningful benefit at 18 months in mild cognitive impairment or mild Alzheimer's dementia, plus about 107 more ARIA-E cases per 1,000. Only two trials tested approved drugs, which critics call a key limitation.</p><p><a href="https://mastodon.social/tags/medicine" rel="tag">#<span>medicine</span></a> <a href="https://mastodon.social/tags/alzheimer" rel="tag">#<span>alzheimer</span></a> <a href="https://mastodon.social/tags/dementia" rel="tag">#<span>dementia</span></a> </p><p><a href="https://psyll.com/articles/science/medicine-health/why-alzheimers-drugs-may-miss-the-clinical-mark" rel="nofollow noopener"><span>https://</span><span>psyll.com/articles/science/med</span><span>icine-health/why-alzheimers-drugs-may-miss-the-clinical-mark</span></a></p>]]></description><link>https://postcall.pub/topic/7b929113-ec0c-4db6-88ce-a84ece94dff2/a-cochrane-systematic-review-april-2026-pooled-17-randomised-trials-with-20-342-participants.</link><generator>RSS for Node</generator><lastBuildDate>Sun, 22 Nov 2026 23:38:41 GMT</lastBuildDate><atom:link href="https://postcall.pub/topic/7b929113-ec0c-4db6-88ce-a84ece94dff2.rss" rel="self" type="application/rss+xml"/><pubDate>Wed, 04 Nov 2026 17:53:53 GMT</pubDate><ttl>60</ttl></channel></rss>